Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry

Table 2

Clinical outcomes in matched population at 3-year follow-up.

	Total (n = 7,389)	EES (n = 2,463)	BES (n = 2,463)	ZES (n = 2,463)	value
Target lesion failure	485 (6.6%)	145 (5.9%)	166 (6.7%)	174 (7.1%)	0.226
POCO^†	997 (13.5%)	312 (12.7%)	332 (13.5%)	353 (14.3%)	0.232
All-cause death	431 (5.8%)	135 (5.5%)	141 (5.7%)	155 (6.3%)	0.459
Cardiac death	255 (3.5%)	78 (3.2%)	78 (3.2%)	99 (4.0%)	0.167
Myocardial infarction	97 (1.3%)	29 (1.2%)	33 (1.3%)	35 (1.4%)	0.746
Target vessel myocardial infarction	50 (0.7%)	11 (0.4%)	21 (0.9%)	18 (0.7%)	0.204
Any revascularization	585 (7.9%)	180 (7.3%)	203 (8.2%)	202 (8.2%)	0.390
Target lesion revascularization	238 (3.2%)	68 (2.8%)	95 (3.9%)	75 (3.0%)	0.078
Stent thrombosis^‡	47 (0.6%)	15 (0.6%)	19 (0.8%)	13 (0.5%)	0.549
Major bleeding	78 (1.1%)	28 (1.1%)	22 (0.9%)	28 (1.1%)	0.627

Values are n (%), unless otherwise indicated. Target lesion failure defined as a composite of cardiac death, MI (not clearly attributed to a nontarget vessel), or target lesion revascularization. ^†POCO includes all-cause mortality, any MI (includes nontarget vessel territory), and revascularization. ^‡Stent thrombosis includes definite and probable stent thrombosis. EES = everolimus-eluting stent; BES = biolimus-eluting stent; ZES = zotarolimus-eluting stent; POCO = patient-oriented composite outcome; MI = myocardial infarction.